Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. (17th June 2019)

• Record Type: Journal Article
• Authors: Roche, Daniel J O; Trela, Constantine J; Argos, Maria; Jasmine, Farzana; Kibriya, Muhammad G; Ahsan, Habibul; King, Andrea C
• Is Part Of: Alcohol and alcoholism. Volume 54:Number 5(2019)
• Page Start: 559
• Page End: 565
• Publication Date: 2019-06-17
• Subjects: Alcoholism -- Periodicals; 616.861005
• DOI: 10.1093/alcalc/agz046
• Languages: English
• ISSNs: 0735-0414

Abstract

Abstract : No significant associations were found between opioid-receptor gene single nucleotide polymorphisms (SNPs) and naltrexone's effects on the clinical trial endpoints of smoking quit rate, weight gain, and heavy drinking behavior. Abstract: Aims: The present study examined how variation in mu- ( OPRM1 ), kappa- ( OPRK ), and delta- ( OPRD ) opioid receptor genes may influence the efficacy of naltrexone in the context of a smoking cessation trial. Methods: The study's primary objective was to examine the association of the Asn40Asp OPRM1 single nucleotide polymorphism (SNP) with naltrexone's effects on smoking quit rate, weight gain, and heavy drinking behavior during a double-blind, randomized clinical trial in 280 adult DSM-IV nicotine-dependent participants. The secondary goal of the study was to examine the relationship of 20 additional SNPs of OPRM1, OPRK, and OPRD with the aforementioned outcomes. Results: Results indicated a null association between any opioid-receptor gene SNP and naltrexone's effects on smoking quit rate, weight gain, and heavy drinking behavior in this sample of nicotine dependent participants. Conclusions: In sum, these results do not suggest that genetic variation in opioid-receptors is related to treatment responses to naltrexone in a smoking cessation trial.